This week on NephTrials we will discuss the PROTECT-V trial, a platform trial for preventing COVID-19 infections in the vulnerable kidney populations.
🤔 Starting ARB in hospitalized COVID, an RCT
Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial (Jardine, The BMJ 2022)
🤔 RASi might be harmful in COVID
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19 (REMAP-CAP Investigators, JAMA 2023)
The NephJC Summer Book Club: 'Codebreaker'
COVID-19 and Vaccines and mABs, Oh My!
Fellowship in COVID-19 the visual abstract
Thanks to Shina Menon for putting together this visual abstract
Nephrology Fellowship and COVID-19
Vexed about Vaccines? Ed Explains
VACCINES
Renalism Returns with Remdesivir
TRANSPLANT
This page discusses the common questions transplant professionals as well as transplant patients may have with COVID-19. We have few facts and little evidence, and those are laid out below. Locally, the decisions being taken depend on local resources, logistics and other factors, and hence local practice may appropriately vary.
PEDIATRICS
COVID-19, the disease caused by SARS-CoV-2, has rapidly become a global pandemic. This review aims to complement the other NephJC pages with a focus on how children with kidney disease are impacted by this pandemic. Our aim is to review what we know about COVID-19 as it pertains to kidney disease in kids.
DIALYSIS and CKD
ACUTE KIDNEY INJURY
As with all the other pages on COVID-19 here on NephJC, this page on AKI & the discussion are not meant to be treatment recommendations based on sound evidence. Our aim on this page is to merely discuss the science of what we know, and some of the biology and mechanisms as well as practical management aspects.
ACE2 and HYPERTENSION
There has been an unprecedented interest in this topic. Hence we have added more details and moved this section from the main page to a dedicated area with focus on hypertension and ACE2. Curated by Matt Sparks and Swapnil Hiremath, with additional expert input from the COVID-ACE2 workgroup